Background: Coronavirus pandemic is currently a global public health emergency. At present, no pharmacological treatment is known to treat this condition, and there is a need to review the available treatments.Objective: While there have been studies to describe the role of chloroquine and hydroxychloroquine in various viral conditions, there is limited information about the use of them in COVID-19. This systematic review aims to summarize the available evidence regarding the role of chloroquine in treating coronavirus infection. Methods:The preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines were used for this review.were pre-prints (not yet peer-reviewed) articles) in this systematic review. All the articles mentioned about the role of chloroquine and /or hydroxychloroquine in limiting the infection with SARS-CoV-2 (the virus causing COVID-19). Conclusions:There is theoretical, experimental, preclinical and clinical evidence of the effectiveness of chloroquine in patients affected with COVID-19. There is adequate evidence of drug safety from the long-time clinical use of chloroquine and hydroxychloroquine in other indications. More data from ongoing and future trials will add more insight into the role of chloroquine and hydroxychloroquine in COVID-19 infection.

Background: India has the most number of COVID-19 cases currently in the world, second only to the USA. The COVID-19 pandemic has caused high mortality not only in patients but also health care providers. In this paper, our aim is to analyze the cases of deaths among Indian doctors due to COVID-19 infection. Methods: The details of data were taken from the list of the deceased doctors in India due to COVID-19 infection, which was compiled by the Indian Medical Association (IMA), the top body of Indian doctors practicing modern allopathic medicine. The key data fields of age, specialty, and geographical location of the deceased doctors were extracted from the given list, and analysis was performed. Results: A total of 382 COVID-related deaths and 2174 infections were reported amongst doctors in India till 10 September 2020, with a case fatality rate of 16.7% among Indian doctors, which was ten times the CFR of 1.7% in the general population. Among the practicing doctors, after excluding the resident doctors and house surgeons, the CFR was 36.4%, which is almost 22 times more than what was seen in Indian general population. The average age of COVID-related deaths in Indian doctors was 60.8 years, with a median age of 60; 62% of deaths among doctors were in the above 60 years, age group. The maximum number of deceased doctors were amongst general practitioners 225(58.9%). Among the specialists, most deaths were seen in paediatricians 26(6.8%), medical specialists 24(6.3%), general surgeons 22(5.8%), obstetricians & gynecologists 16(4.2%), and anesthesiologists 14(3.7%). The highest COVID-19 related deaths in doctors were seen in the Indian states of Tamil Nadu, Karnataka, Andhra Pradesh, Gujarat and Maharashtra in that order. Conclusions: The mortality rate is very high among doctors in India compared to the general population. The average age of COVID-19 related death was 60 years among doctors. General practitioners and 60 years+ doctors are at a much higher risk of mortality among the doctors. The states with the high number of COVID-19 cases in India, also had a higher number of doctor deaths.

Background: Full immunization with two doses of Covid vaccine has been found to be a critical factor in preventing morbidity and mortality from the Covid-19 infection. However, due to the shortage of vaccines, a significant portion of the population is not getting vaccination in many countries. Also, the distribution of vaccine doses between prospective first dose recipient and second dose recipient is not uniformly planned, as seen in India's various states and union territories. It is recommended to give second vaccine doses within 4-8 weeks to first dose recipients for both the approved vaccines in India; hence the judicious distribution between non-immunized and partly immunized populations is essential. Managing the Covid-19 vaccination drive in an area with a large number of single-dose recipients compared to a smaller number of fully immunized people can become a huge administrative challenge. Therefore, this study was conducted to assess the number of people covered under the Covid vaccination drive in India and analyze the state-wise distribution of vaccines among the non-immunized and partly immunized population. Methods: The Covid 19 vaccination data till 7th may, 2021 was taken from the website of the Ministry of Health and Family Welfare, Govt of India. From the data available of the number of doses injected, other figures like the total number of people vaccinated, people with two doses of vaccine or full immunization (FI), and those with a single dose of vaccine or partial immunization (PI) were found. The percentage of the fully immunized and partly immunized population was also found. A ratio between fully immunized and partly immunized individuals (FI: PI) was proposed as a guide to monitor the progress of the vaccination and future dose distribution of two-dose Covid-19 vaccines among partly immunized (PI) and non-immunized (NI) population. Results: In India, till 7 May 2021, 16,49,73,058 doses of Covid-19 vaccines have been injected. A total of 13,20,87,824 people received these vaccine doses, with 9,92,02,590 people getting a single dose or were partly immunized (PI), and 3,28,85,234 got two doses each or were fully immunized (FI). Among the states, Tripura and Andhra Pradesh had the highest FI: PI (Fully Immunized: Partly Immunized) ratio of 0.86 and 0.52, followed by Tamil Nadu, Arunachal Pradesh, and West Bengal with figures of 0.48. 0.47 and 0.47, respectively. Telangana and Punjab had the lowest FI: PI ratio among the states at 0.2 each, with Chhattisgarh, Madhya Pradesh, and Haryana following at 0.21. 0.23 and 0.23, respectively. These values are much lower than the national average of 0.33 in India. Conclusion: The FI: PI ratio could help governments decide how to use scarce vaccine resources among first-time and second-time recipients. This simple mathematical tool could ensure full immunization status to maximum people within the recommended 4-8 week time window after the first dose to avoid a large population group with partly immunized status.